Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL NETS
ACTRN12615000909527Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, temozolomide and lutetium Lu 177 dotatate in islet cell tumor and midgut neuroendocrine tumor (MNET) (4 cohorts), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Progression-free survival at 12 months in pancreatic neuroendocrine tumors and 24 months in midgut neuroendocrine tumors. Started Dec 2015; status: completed.
02
Drugs
capecitabinetemozolomidelutetium Lu 177 dotatate
03
Conditions
islet cell tumormidgut neuroendocrine tumor (MNET)
Beyond the preview
Go deeper on ACTRN12615000909527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000909527.